All In Biotech

Drug Trial Radar · NCT07107204

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

A Multicenter, Open-label, Single-arm Phase Ib/IIa Clinical Study to Evaluate the Safety and Efficacy of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Oct 2025

Primary completion

Jan 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Biotroy TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

  • Relapsed or Refractory Hematologic Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma (MM)

Interventions

  • BT02Drug

    BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Through the study completion, an average of 2.5 years
  2. Dose limited toxicity(DLT)Time frame: Through the dose escalation phase, an average of 10 months
  3. Maximum tolerable dose(MTD)Time frame: Through the dose escalation phase, an average of 10 months
  4. Recommended phase 2 dose(RP2D)Time frame: Through the study completion, an average of 2.5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.